Systemic Lupus Erythematosus Treatment Market
Latest Trends and Developments
Systemic Lupus Erythematosus (SLE) is chronic autoimmune disorder. It is characterized by
excess production of the antibodies that attacks body’s own cells and vital organs. Various
symptoms associated with the disease includes joint pain, swelling, rashes over face (butterfly
rash) and other body area, severe fatigue, hair loss, anemia, and Raynaud’s phenomenon etc.
SLE can also affect vital body organs such as heart, kidney, lungs, and behavioral changes.
Exact causes of the disease is unknown, however, hereditary and environmental factors could be
lead to SLE. There is no direct cure available for SLE, however, symptomatic treatment can be
administered to lower or eliminate symptoms associated with disease. Major classes of drugs
commonly used are antimalarial agents such as chlorquine and hydrochlorquine; topical steroid
cream for rashes; NSAIDS for joint pain; and fever steroidal medication such as glucocorticoids
through IV or oral route and immunosuppressive agents to lower immune response from the
antibodies.
Request Sample Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/1540
Market dynamics
Rise in incidence of SLE is one of major factors driving growth of the systemic lupus
erythematosus treatment market. According to study published in the Expert Review of Clinical
Immunology in 2017, the global incidence rate varied from about 0.3–23.7 per 100,000 person
and the prevalence rates varied in the range from 6.5 to 178.0 per 100,000 people. Key
companies are entering into collaborations for research and development in systemic lupus
erythematosus, which is expected to support growth of the market. For instance, in 2015, a
genomic mapping company, 23andMe, Inc. collaborated with Pfizer, Inc. to study and
understand the genetics of lupus thereby, to develop treatment for it. In 2012, Alliance for
Lupus Research and Pfizer’s Centers for Therapeutic Innovation collaborated to discover new
therapies for patients living with systemic lupus erythematosus. Increasing approvals for
products for the treatment of SLE is another factor expected to aid in growth of the market.